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T he first-line therapy for idiopathic thrombocytope-nic purpura (ITP) is prednisolone at 1 mg/kg/day 
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Standard therapy for idiopathic thrombocytopenic purpura (ITP) has not been established.  We are conducting 
a multicenter,  prospective trial to determine the efficacy and safety of short-term,  high-dose dexamethasone 
therapy in ITP patients aged 18-80 years with platelet counts of < 20, 000 /µL,  or with < 50, 000/ µL and bleed-
ing symptoms.  The primary endpoints of this trial are the proportion of responses (complete plus partial 
response) on day 180 (day 46 + 180) after the completion of the 46-day high-dose dexamethasone therapy.  The 
results of this investigation of the effectiveness and safety of this regimen will be essential for the establishment 
of standard therapy for ITP.
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continuously for 2-4 weeks,  followed by tapering (stan-
dard-dose prednisolone therapy).  This regimen is 
widely used worldwide and is recommended in the 
clinical guidelines [1 , 2] of several countries.  However,  
the regimen is not based on the results of high-quality,  
randomized controlled trials (RCTs); it is ultimately 
empiric therapy.  Approximately 80% of ITP patients 
show some improvement from prednisolone treatment,  
and the platelet count recovers to > 100,000 /µL in 50% 
of the patients [1 , 6].  Nevertheless,  thrombocytopenia 
often recurs during prednisolone therapy weaning.  It is 
considered that only 10-20% of patients will be able to 
discontinue prednisolone due to a relapse-free state 
[3 , 4],  but long-term therapy with a steroid such as 
prednisolone can reduce an individual’s quality of life 
and lead to side effects,  including susceptibility to 
infections and osteoporosis.
Short-term,  high-dose dexamethasone therapy has 
been administered to patients who are resistant to stan-
dard-dose prednisolone therapy,  and in Japan this 
approach was confirmed to have achieved some thera-
peutic effects.  Chen et al.  [5] and Mazzucconi et al.  [6] 
reported the effects of high-dose dexamethasone for 
treating the initial manifestations of ITP.  In a multi-
center,  prospective trial,  Mazzucconi et al.  adminis-
tered 40-mg dexamethasone for 4 days to 95 patients 
with newly diagnosed ITP,  repeated every 2 weeks for a 
total of 4 courses [6].  Those authors reported some 
therapeutic effect in 85.6% of the patients,  and a pro-
gression-free survival rate of 81% after 15 months.  
There were no particular safety issues associated with 
the treatment.  Since the number of patients who expe-
rienced a therapeutic effect did not significantly 
increase from the third to the fourth course,  the sub-
jects in that RCT will now receive 3 courses of stan-
dard-dose prednisolone and high-dose dexamethasone.
Mashhadi et al.  [7] reported the results of a prospec-
tive RCT that examined the effect of one course of 
either standard-dose prednisolone or high-dose dexa-
methasone,  with 30 patients in each group.  Signifi- 
cantly better results were observed in the high-dose 
dexamethasone group in terms of both the 3-month 
complete response (CR) rate (80% vs.  23.3%; p<0.0001) 
and the 6-month CR rate (73.3% vs.  16.7%; p<0.0001).  
The authors did not observe any differences between the 
groups with respect to treatment-related side effects.
In Japan,  Sakamoto et al.  [8] retrospectively com-
pared 31 patients who received high-dose dexametha-
sone with 69 patients who received standard-dose pred-
nisolone.  They reported a significantly better treatment 
response (42.7% vs. 28.4%) and a significantly better 
steroid withdrawal rate after 6 months (64.5% vs.  37.7%) 
in the high-dose dexamethasone group compared to the 
standard-dose prednisolone group; no differences in 
toxicity were observed.  In contrast,  Nakazaki et al.  [9] 
conducted a retrospective study comparing 8 patients 
who received standard-dose prednisolone,  12 patients 
who received one course of high-dose dexamethasone,  
and 5 patients who received three courses of high-dose 
dexamethasone; they observed a better long-term ther-
apeutic effect in the prednisolone group.
No prospective investigation of high-dose dexa-
methasone therapy for ITP has been reported in Japan.  
Thus,  a multicenter,  prospective investigation of the 
effectiveness and safety of this regimen is essential for 
the establishment of a standard therapy for ITP.  After 
the verification of the effectiveness of high-dose dexa-
methasone therapy,  the confirmation of its early-,  
mid-,  and long-term effects could help prevent the 
adverse events associated with long-term steroid ther-
apy.  With this in mind,  and based on the results of 
clinical trials already reported and in progress,  we 
chose as our primary endpoint the efficacy on day 180 
after the completion of the 46-day high-dose dexameth-
asone therapy (day 46 + 180).
Japan is unique in that Helicobacter pylori eradication 
is emphasized in the treatment of ITP.  A clinical refer-
ence guide [1] published in 2012 by a team studying 
coagulopathies as part of the Japanese Ministry of 
Health,  Labour and Welfare’s research initiative for 
treating intractable diseases states that the initial 
approach to treatment should involve testing for H. pylori, 
with the provision of eradication therapy in positive 
cases.  This recommendation was put forward because 
clinical trials and other studies had shown that platelet 
levels rise in approx.  50% of ITP patients who still test 
positive for H. pylori infection after receiving 
H. pylori eradication therapy.
Clinical trials conducted outside of Japan regarding 
the use of high-dose dexamethasone therapy in the con-
text of ITP do not address H. pylori eradication.  In 
clinical practice,  patients similar to the subjects in the 
present trial (platelet count < 20,000 /µL or with bleed-
ing symptoms) would first have steroids administered.  
Then,  after the demonstration of some therapeutic 
effect,  eradication therapy would be initiated based on 
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testing for H. pylori infection.  The reference guide pub-
lished in Japan [1] also recommends eradication ther-
apy in patients with markedly low platelet levels and 
bleeding symptoms,  but only after some therapeutic 
effect from the treatment has been observed.  In the 
present trial,  eradication therapy was administered to 
patients who tested positive for H. pylori after the initi-
ation of treatment,  and the safety of this therapeutic 
approach was investigated.
Diagnosis by exclusion is the basic method for diag-
nosing ITP,  as no useful diagnostic markers of ITP have 
been identified.  It can thus be difficult to differentiate 
ITP from other diseases that also involve thrombocyto-
penia.  Plasma thrombopoietin levels and other markers 
have been found to be useful in differentiating ITP from 
other diseases [10].  In the present trial,  the measure-
ments performed at the start of therapy could offer new 
insights related to the therapeutic responsiveness or 
other factors.
Endpoints
The primary endpoints of this trial are the propor-
tion of responses (complete + partial responses) on day 
180 (day 46 + 180) after the patients complete the high-
dose dexamethasone therapy (which will be completed 
46 days after starting treatment).  The secondary end-
points are the platelet count on day 46 + 180 (by 
response,  complete response,  and partial response),  
relapse-free survival,  the frequency of adverse events,  
the frequency of H. pylori infection,  the bacterial erad-
ication effect,  the proportion of complete responses on 
day 46 + 180 among the patients without H. pylori infec-
tion,  the proportion of complete responses on day 
46+ 180 among the patients with H. pylori infection with 
eradication/no eradication effect,  the relapse-free sur-
vival for the patients without H. pylori infection,  the 
relapse-free survival for patients with H. pylori infection 
with eradication/no eradication effect,  and the adverse 
events with eradication/no eradication effect.
Eligibility Criteria
Inclusion criteria. (1) Patients ≥ 18 years old and 
≤ 80 years old at registration.  (2) Patients newly diag-
nosed with ITP and assessed as requiring treatment.  (3) 
Platelet count of <20,000 /µL,  or <50,000 /µL with bleed-
ing symptoms.  (4) Performance status of 0-2 at regis-
tration.  (5) Patients who receive a full explanation of 
the trial from an investigator or sub-investigator at an 
institution participating in the trial with the use of an 
informed consent form,  and who themselves (or their 
guardians for minors) voluntarily give written consent 
to participate in the trial.
Exclusion criteria. (1) Active malignant disease 
at registration.  (2) Administration of antiplatelet or 
anticoagulant drugs.  (3) Mental illness.  (4) Pregnant or 
breast-feeding women.  (5) Cardiovascular disease that 
requires treatment.  (6) Treatment-resistant hyperten-
sion or diabetes.  (7) Liver or kidney dysfunction (creat-
inine,  aspartate transaminase [AST],  or alanine trans-
aminase [ALT] levels ≥2 times the upper limit of normal).  
(8) Positive test result for hepatitis C virus (HCV) anti-
bodies,  human immunodeficiency virus (HIV) anti-
bodies,  or hepatitis B surface protein (HBs) antigen.  
(9) Chronic liver disease.  (10) History of a viral infec-
tion,  positivity for immunoglobulin M (IgM),  or vacci-
nation within the last month.  (11) Initiation of a new 
drug within 1 week of diagnosis.  (12) Active gastroin-
testinal ulcer disease.  (13) Serious intracerebral or gas-
trointestinal hemorrhage.  (14) Continuous administra-
tion of a steroid hormone or immunosuppressant for 
another disease.  (15) Otherwise deemed unsuitable for 
the trial by a sub-investigator.
Methods
Study design. This study is a multicenter,  open- 
label,  single-arm trial.  The study was approved by the 
central review board of Japan’s National Hospital 
Organization for clinical trials (H28-0810001).  The 
registration of trial participants began in March 2016.  
We are currently recruiting participants.  The study was 
registered in the University Hospital Medical Information 
Network Center (UMIN)-Clinical Trials Registry (CTR) 
on May 23, 2016 (UMIN 000022415). The trial’s design 
is shown in Fig.1.
High-dose dexamethasone therapy. Three courses 
of high-dose dexamethasone therapy will be adminis-
tered every 2 weeks.  One course consists of dexameth-
asone 40 mg orally,  administered daily for 4 days,  or 
dexamethasone 30.2 mg intravenously,  administered 
daily for 4 days.  The attending physician can decide 
between oral or intravenous administration.  If the 
patient’s platelet count is < 20,000 /µL after 4 days of the 
investigational drug,  up to 2 mg of dexamethasone may 
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be administered.  Patients who exhibit steroid with-
drawal symptoms or are deemed to be at high risk for 
these symptoms may have up to 2 mg of dexametha-
sone administered.  Regardless of the platelet count or 
other symptoms,  weaning should be performed so that 
dexamethasone administration ends by day 14 after the 
end of the third course.
Helicobacter pylori eradication therapy. Patients 
are tested for H. pylori at the time of diagnosis.  A stool 
test for H. pylori antigen is recommended,  but the test 
selection is left to the discretion of the attending physi-
cian.  After the beginning of the trial,  eradication ther-
apy may be given at any point if a patient is found to be 
positive for H. pylori.  This therapy consists of a 7-day 
course of 3 drugs (amoxicillin 1,500 mg,  clarithromy-
cin 400 mg,  and a proton pump inhibitor [PPI]) given 
in 2 divided doses per day (after breakfast and after 
dinner).  Following this treatment course,  the success of 
the eradication is assessed over the next 4-8 weeks via 
stool tests for H. pylori antigen or the urea breath test.  If 
eradication is unsuccessful,  a second round of therapy 
is administered,  replacing clarithromycin with metro-
nidazole (amoxicillin 1,550 mg,  metronidazole 500 mg,  
and PPI),  and the effects are again assessed over the 
next 4-8 weeks.
Antiviral therapy. Patients who test positive for 
HBs antibodies or hepatitis B core (HBc) antibodies will 
not be excluded from the trial,  but the trial therapy 
carries a risk of hepatitis B virus (HBV) reactivation.  
These patients should be monitored for HBV DNA with 
polymerase chain reaction (PCR) every 1 or 2 months 
for ≥ 6 months after completing treatment.  Patients who 
test positive should receive aggressive antiviral therapy.
Preventing gastrointestinal ulcers and infections.
A gastrointestinal ulcer drug (PPI or H2-blocker) will be 
administered during oral dexamethasone therapy.  
Antituberculosis drugs,  trimethoprim-sulfamethoxazole,  
antifungal drugs,  and antiviral drugs will be used to 
prevent infections at the discretion of the attending 
physician.
Statistical Considerations
Sample size. In a retrospective study performed 
in Japan,  the complete response (CR) rate after 1 year of 
prednisolone administration was 28.4% [8].  In a regis-
try in Japan,  the proportion of responses (CR + partial 
response [PR]) at 2 years after diagnosis was 75.0% 
(114/152) [11].  In a prospective interventional study 
from Iran,  the CR + PR rate of the group that received 
standard steroid treatment was 53.3% (16/30) and 
46.7% (14/30) after 6 months and 1 year,  respectively 
[7].  Based on these results,  we chose 50% as the 
threshold proportion of response.
The response rate at ≥ 2 months after the completion 
of therapy according to the GIMEMA (Gruppo Italiano 
per le Malattie Ematologiche dell’Adulto) protocol was 
83.8% (31/37) in a single-center study and 84.4% (76/90) 
in a multicenter study [6].  Based on these results,  we 
chose 80% as the expected proportion of response.  The 
number of patients needed was calculated to be 21 
based on binomial proportion with a significance level 
of 0.05 (one-tailed) and detection power of 0.90.  To 
account for dropouts,  we set the sample size as 25.
Interim analysis and monitoring. An interim 
analysis will not be conducted.  Monitoring will be per-
formed regularly once per year.  Data collected from the 
internet will be subject to central monitoring,  but insti-
tutions will not be monitored by means of site visits.
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Screening 
・ITP patients who need treatment 
(platelet count≤20,000 /µL, or ≤50,000 /µL with bleeding symptoms) 
・≥18 and≤80 years of age 
・PS 0-2 
Registration 
(28 days before start of therapy ‒ Start of therapy [day 1]) 
Trial therapy 
HDD (high-dose dexamethasone therapy)×3 courses 
(day 1, day 15, day 29) 
Dexamethasone 40 mg for 4 days: One course 
administered by either: 
・Oral: 40 mg once per day 
・Intravenous injection: 30.2 mg 
Assessment of results 
(day 46+180)
Post-treatment observation
(1 year, 2 years)
Combined with 
eradication therapy for 
H. pylori-positive cases
Fig. 1　 The design of the present multicenter,  open-label,  sin-
gle-arm trial.
Discussion
A standard therapy for ITP has not yet been estab-
lished.  It is hoped that this trial will assist in the estab-
lishment of a standard therapeutic regimen.  This trial 
cannot reach any further than an explanatory study,  and 
the trial’s results should thus be verified in a random-
ized controlled trial.
Acknowledgments　This study is supported by a collaborative clinical 
research grant from Japan’s National Hospital Organization.
References
 1.  Fujimura K,  Miyakawa Y,  Kurada Y,  Kuwana M,  Toyama Y and 
Murata M: [Reference guide for treating adult idiopathic thrombo-
cytopenic purpura (ITP) 2012 version].  Rinsho Ketsueki (2012) 
53: 433-442 (in Japanese).
 2. Neunert C,  Lim W,  Crowther M,  Cohen A,  Solberg Jr. L and 
Crowther MA: The American Society of Hematology 2011 evi-
dence-based practice guide line for immune thrombocytopenia.  
Blood (2011) 117: 4190-4207.
 3. Stasi R,  Stipa E,  Masi M,  Cecconi M,  Scimo M,  Oliva F,  Sciarra A,  
Perrotti AP,  Adomo G,  Amadori S and Papa G: Long-term obser-
vation of 208 adults with chronic idiopathic thrombocytopaenic pur-
pura.  Am J Med (1995) 98: 436-442.
 4. Zimmer J,  Andres E,  Noel E,  Koumarianou A,  Blickle JF and 
Maloisel F: Current management of adult idiopathic thrombocyto-
penic purpura in practice: a cohort study of 201 patients from a 
single center.  Clin Lab Haematol (2004) 83126: 137-142.
 5. Cheng Y,  Wong RSM and Soo YO: Initial treatment of immune 
thrombocytopenic purpura with high-dose dexamethasone.  New 
Engl J Med (2003) 349: 831-836.
 6. Mazzucconi MG,  Fazi P,  Bemasconi S,  De Rossi G,  Leone G,  
Gugliotta L,  Vianelli N,  Avvisati G,  Rodeghiero F,  Amendola A,  
Baronci C,  Carbone C,  Quattrin S,  Fioritoni G,  DʼAlfonso G,  
Mandelli F and Gruppo Italiano Malattie EMatologiche dellʼAdulto 
(GIMEMA) Thrombocytopenia Working Party: Therapy with high-
dose dexamethasone (HD-DXM) in previously untreated patients 
aﬀected by idiopathic thrombocytopenic purpura: a GIMEMA expe-
rience.  Blood (2007) 109: 1401-1407.
 7. Mashhadi MA,  Kaykhaei MA,  Sepehri Z and Miri-Moghaddam E:  
Single course of high dose dexamethasone is more eﬀective than 
conventional prednisolone therapy in the treatment of primary 
newly diagnosed immune thrombocytopenia.  Daru (2012) 20: 7.
 8. Sakamoto K,  Nakasone H,  Tsurumi S,  Sasaki K,  Mitani K,  Kida M,  
Hangaishi A,  Usuki K,  Kobayashi A,  Sato K,  Karasawa-
Yamaguchi M,  Izutsu K,  Okoshi Y,  Chiba S and Kanda Y:  
Prednisone versus high-dose dexamethasone for untreated primary 
immune thrombocytopenia.  A retrospective study of the Japan 
Hematology & Oncology Clinical Study Group.  J Thromb Thrombolysis 
(2014) 37: 279-286.
 9. Nakazaki K,  Hosoi M,  Hangaishi A,  Ichikawa M,  Nannya Y and 
Kurokawa M: Comparison between pulsed high-dose dexametha-
sone and daily corticosteroid therapy for adult primary immune 
thrombocytopenia: a retrospective study.  Intern Med (2012) 51:  
859-863.
10. Hiyoyama K,  Wada H,  Shimura M,  Nakasaki T,  Katayama N,  
Nishikawa M,  Shiku H,  Tahara T and Kato T: Increased serum 
levels of thrombopoietin in patients with thrombotic thrombocytope-
nic purpura,  idiopathic thrombocytopenic purpura,  or disseminated 
intravascular coagulation.  Blood Coagul Fibrinolysis (1997) 
8: 345-349.
11. Portielje JE,  Westendorp RG,  Kluin-Nelemans HC and Brand A:  
Morbidity and mortality in adults with idiopathic thrombocytopenic 
purpura.  Blood (2001) 97: 2549-2554.
April 2018 ITP: Initial High-dose Dexamethasone 201
